WEST PHARMACEUTICAL SERVICES (WST) Fundamental Analysis & Valuation

NYSE:WST • US9553061055

Current stock price

254.665 USD
-0.14 (-0.05%)
Last:

This WST fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

7

1. WST Profitability Analysis

1.1 Basic Checks

  • WST had positive earnings in the past year.
  • In the past year WST had a positive cash flow from operations.
  • WST had positive earnings in each of the past 5 years.
  • WST had a positive operating cash flow in each of the past 5 years.
WST Yearly Net Income VS EBIT VS OCF VS FCFWST Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

1.2 Ratios

  • WST has a Return On Assets of 11.56%. This is amongst the best in the industry. WST outperforms 92.98% of its industry peers.
  • WST's Return On Equity of 15.54% is amongst the best of the industry. WST outperforms 91.23% of its industry peers.
  • WST has a better Return On Invested Capital (14.09%) than 94.74% of its industry peers.
  • Measured over the past 3 years, the Average Return On Invested Capital for WST is above the industry average of 11.38%.
Industry RankSector Rank
ROA 11.56%
ROE 15.54%
ROIC 14.09%
ROA(3y)13.53%
ROA(5y)15.35%
ROE(3y)18.17%
ROE(5y)20.93%
ROIC(3y)15.83%
ROIC(5y)17.92%
WST Yearly ROA, ROE, ROICWST Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5 10 15 20 25

1.3 Margins

  • The Profit Margin of WST (16.06%) is better than 84.21% of its industry peers.
  • In the last couple of years the Profit Margin of WST has remained more or less at the same level.
  • WST has a Operating Margin of 20.53%. This is amongst the best in the industry. WST outperforms 87.72% of its industry peers.
  • In the last couple of years the Operating Margin of WST has remained more or less at the same level.
  • WST's Gross Margin of 35.91% is on the low side compared to the rest of the industry. WST is outperformed by 61.40% of its industry peers.
  • In the last couple of years the Gross Margin of WST has remained more or less at the same level.
Industry RankSector Rank
OM 20.53%
PM (TTM) 16.06%
GM 35.91%
OM growth 3Y-7.75%
OM growth 5Y1.08%
PM growth 3Y-7.51%
PM growth 5Y-0.08%
GM growth 3Y-3.01%
GM growth 5Y0.08%
WST Yearly Profit, Operating, Gross MarginsWST Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10 20 30 40

8

2. WST Health Analysis

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), WST is creating some value.
  • WST has less shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, WST has less shares outstanding
  • WST has a better debt/assets ratio than last year.
WST Yearly Shares OutstandingWST Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M
WST Yearly Total Debt VS Total AssetsWST Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B 4B

2.2 Solvency

  • An Altman-Z score of 13.09 indicates that WST is not in any danger for bankruptcy at the moment.
  • With an excellent Altman-Z score value of 13.09, WST belongs to the best of the industry, outperforming 98.25% of the companies in the same industry.
  • The Debt to FCF ratio of WST is 0.44, which is an excellent value as it means it would take WST, only 0.44 years of fcf income to pay off all of its debts.
  • WST has a Debt to FCF ratio of 0.44. This is amongst the best in the industry. WST outperforms 92.98% of its industry peers.
  • WST has a Debt/Equity ratio of 0.06. This is a healthy value indicating a solid balance between debt and equity.
  • WST's Debt to Equity ratio of 0.06 is fine compared to the rest of the industry. WST outperforms 66.67% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.06
Debt/FCF 0.44
Altman-Z 13.09
ROIC/WACC1.29
WACC10.88%
WST Yearly LT Debt VS Equity VS FCFWST Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B

2.3 Liquidity

  • WST has a Current Ratio of 3.02. This indicates that WST is financially healthy and has no problem in meeting its short term obligations.
  • WST's Current ratio of 3.02 is in line compared to the rest of the industry. WST outperforms 56.14% of its industry peers.
  • A Quick Ratio of 2.34 indicates that WST has no problem at all paying its short term obligations.
  • The Quick ratio of WST (2.34) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 3.02
Quick Ratio 2.34
WST Yearly Current Assets VS Current LiabilitesWST Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B

4

3. WST Growth Analysis

3.1 Past

  • The Earnings Per Share has been growing slightly by 8.00% over the past year.
  • WST shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 8.94% yearly.
  • Looking at the last year, WST shows a small growth in Revenue. The Revenue has grown by 6.25% in the last year.
  • Measured over the past years, WST shows a small growth in Revenue. The Revenue has been growing by 7.44% on average per year.
EPS 1Y (TTM)8%
EPS 3Y-5.25%
EPS 5Y8.94%
EPS Q2Q%12.09%
Revenue 1Y (TTM)6.25%
Revenue growth 3Y2.12%
Revenue growth 5Y7.44%
Sales Q2Q%7.51%

3.2 Future

  • The Earnings Per Share is expected to grow by 9.50% on average over the next years. This is quite good.
  • The Revenue is expected to grow by 5.60% on average over the next years.
EPS Next Y11.14%
EPS Next 2Y11.07%
EPS Next 3Y11.63%
EPS Next 5Y9.5%
Revenue Next Year6.04%
Revenue Next 2Y6.14%
Revenue Next 3Y6.48%
Revenue Next 5Y5.6%

3.3 Evolution

  • The EPS growth rate is stable: in the next years the growth will be about the same than in the last years.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
WST Yearly Revenue VS EstimatesWST Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 1B 2B 3B 4B
WST Yearly EPS VS EstimatesWST Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2 4 6 8 10

3

4. WST Valuation Analysis

4.1 Price/Earnings Ratio

  • WST is valuated quite expensively with a Price/Earnings ratio of 34.93.
  • 63.16% of the companies in the same industry are more expensive than WST, based on the Price/Earnings ratio.
  • When comparing the Price/Earnings ratio of WST to the average of the S&P500 Index (26.17), we can say WST is valued slightly more expensively.
  • Based on the Price/Forward Earnings ratio of 31.43, the valuation of WST can be described as expensive.
  • Based on the Price/Forward Earnings ratio, WST is valued a bit cheaper than 61.40% of the companies in the same industry.
  • WST is valuated rather expensively when we compare the Price/Forward Earnings ratio to 23.05, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 34.93
Fwd PE 31.43
WST Price Earnings VS Forward Price EarningsWST Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • WST's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. WST is cheaper than 68.42% of the companies in the same industry.
  • Based on the Price/Free Cash Flow ratio, WST is valued a bit cheaper than the industry average as 61.40% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 39.15
EV/EBITDA 22.16
WST Per share dataWST EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 10 20 30 40

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
  • WST has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)3.14
PEG (5Y)3.91
EPS Next 2Y11.07%
EPS Next 3Y11.63%

6

5. WST Dividend Analysis

5.1 Amount

  • With a yearly dividend of 0.32%, WST is not a good candidate for dividend investing.
  • WST's Dividend Yield is rather good when compared to the industry average which is at 0.12. WST pays more dividend than 82.46% of the companies in the same industry.
  • Compared to an average S&P500 Dividend Yield of 1.89, WST's dividend is way lower than the S&P500 average.
Industry RankSector Rank
Dividend Yield 0.32%

5.2 History

  • The dividend of WST has a limited annual growth rate of 5.48%.
  • WST has been paying a dividend for at least 10 years, so it has a reliable track record.
  • WST has not decreased its dividend for at least 10 years, so it has a reliable track record of non decreasing dividend.
Dividend Growth(5Y)5.48%
Div Incr Years33
Div Non Decr Years34
WST Yearly Dividends per shareWST Yearly Dividends per shareYearly Dividends per share 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 0.2 0.4 0.6 0.8

5.3 Sustainability

  • WST pays out 12.40% of its income as dividend. This is a sustainable payout ratio.
  • The dividend of WST is growing, but earnings are growing more, so the dividend growth is sustainable.
DP12.4%
EPS Next 2Y11.07%
EPS Next 3Y11.63%
WST Yearly Income VS Free CF VS DividendWST Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M
WST Dividend Payout.WST Dividend Payout, showing the Payout Ratio.WST Dividend Payout.PayoutRetained Earnings

WST Fundamentals: All Metrics, Ratios and Statistics

WEST PHARMACEUTICAL SERVICES

NYSE:WST (4/6/2026, 12:14:05 PM)

254.665

-0.14 (-0.05%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)02-12
Earnings (Next)04-23
Inst Owners97.62%
Inst Owner Change0%
Ins Owners0.33%
Ins Owner Change0.38%
Market Cap18.36B
Revenue(TTM)3.07B
Net Income(TTM)493.70M
Analysts80.87
Price Target328.99 (29.19%)
Short Float %3.58%
Short Ratio2.42
Dividend
Industry RankSector Rank
Dividend Yield 0.32%
Yearly Dividend0.85
Dividend Growth(5Y)5.48%
DP12.4%
Div Incr Years33
Div Non Decr Years34
Ex-Date04-29
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)12.82%
Min EPS beat(2)10.24%
Max EPS beat(2)15.4%
EPS beat(4)4
Avg EPS beat(4)15.68%
Min EPS beat(4)10.24%
Max EPS beat(4)20.68%
EPS beat(8)7
Avg EPS beat(8)12.16%
EPS beat(12)11
Avg EPS beat(12)11.7%
EPS beat(16)14
Avg EPS beat(16)11.27%
Revenue beat(2)2
Avg Revenue beat(2)0.72%
Min Revenue beat(2)0.33%
Max Revenue beat(2)1.1%
Revenue beat(4)4
Avg Revenue beat(4)1.63%
Min Revenue beat(4)0.33%
Max Revenue beat(4)4.33%
Revenue beat(8)7
Avg Revenue beat(8)1.11%
Revenue beat(12)8
Avg Revenue beat(12)0.49%
Revenue beat(16)10
Avg Revenue beat(16)0.34%
PT rev (1m)0%
PT rev (3m)-7.08%
EPS NQ rev (1m)0.09%
EPS NQ rev (3m)2.02%
EPS NY rev (1m)0%
EPS NY rev (3m)3.21%
Revenue NQ rev (1m)0.03%
Revenue NQ rev (3m)2.75%
Revenue NY rev (1m)0.03%
Revenue NY rev (3m)-0.18%
Valuation
Industry RankSector Rank
PE 34.93
Fwd PE 31.43
P/S 5.97
P/FCF 39.15
P/OCF 24.32
P/B 5.78
P/tB 6
EV/EBITDA 22.16
EPS(TTM)7.29
EY2.86%
EPS(NY)8.1
Fwd EY3.18%
FCF(TTM)6.51
FCFY2.55%
OCF(TTM)10.47
OCFY4.11%
SpS42.65
BVpS44.06
TBVpS42.43
PEG (NY)3.14
PEG (5Y)3.91
Graham Number85.01
Profitability
Industry RankSector Rank
ROA 11.56%
ROE 15.54%
ROCE 17.45%
ROIC 14.09%
ROICexc 18.03%
ROICexgc 18.82%
OM 20.53%
PM (TTM) 16.06%
GM 35.91%
FCFM 15.25%
ROA(3y)13.53%
ROA(5y)15.35%
ROE(3y)18.17%
ROE(5y)20.93%
ROIC(3y)15.83%
ROIC(5y)17.92%
ROICexc(3y)20.32%
ROICexc(5y)23.97%
ROICexgc(3y)21.34%
ROICexgc(5y)25.37%
ROCE(3y)19.61%
ROCE(5y)22.21%
ROICexgc growth 3Y-13.74%
ROICexgc growth 5Y-3.06%
ROICexc growth 3Y-13.28%
ROICexc growth 5Y-2.17%
OM growth 3Y-7.75%
OM growth 5Y1.08%
PM growth 3Y-7.51%
PM growth 5Y-0.08%
GM growth 3Y-3.01%
GM growth 5Y0.08%
F-Score7
Asset Turnover0.72
Health
Industry RankSector Rank
Debt/Equity 0.06
Debt/FCF 0.44
Debt/EBITDA 0.26
Cap/Depr 166.8%
Cap/Sales 9.3%
Interest Coverage 2103.33
Cash Conversion 94.07%
Profit Quality 94.98%
Current Ratio 3.02
Quick Ratio 2.34
Altman-Z 13.09
F-Score7
WACC10.88%
ROIC/WACC1.29
Cap/Depr(3y)224.35%
Cap/Depr(5y)223.25%
Cap/Sales(3y)11.53%
Cap/Sales(5y)10.68%
Profit Quality(3y)73.64%
Profit Quality(5y)69.18%
High Growth Momentum
Growth
EPS 1Y (TTM)8%
EPS 3Y-5.25%
EPS 5Y8.94%
EPS Q2Q%12.09%
EPS Next Y11.14%
EPS Next 2Y11.07%
EPS Next 3Y11.63%
EPS Next 5Y9.5%
Revenue 1Y (TTM)6.25%
Revenue growth 3Y2.12%
Revenue growth 5Y7.44%
Sales Q2Q%7.51%
Revenue Next Year6.04%
Revenue Next 2Y6.14%
Revenue Next 3Y6.48%
Revenue Next 5Y5.6%
EBIT growth 1Y7.88%
EBIT growth 3Y-5.8%
EBIT growth 5Y8.6%
EBIT Next Year43.23%
EBIT Next 3Y19.91%
EBIT Next 5Y13.54%
FCF growth 1Y69.65%
FCF growth 3Y2.19%
FCF growth 5Y9.48%
OCF growth 1Y15.52%
OCF growth 3Y1.4%
OCF growth 5Y9.82%

WEST PHARMACEUTICAL SERVICES / WST Fundamental Analysis FAQ

What is the fundamental rating for WST stock?

ChartMill assigns a fundamental rating of 6 / 10 to WST.


What is the valuation status for WST stock?

ChartMill assigns a valuation rating of 3 / 10 to WEST PHARMACEUTICAL SERVICES (WST). This can be considered as Overvalued.


How profitable is WEST PHARMACEUTICAL SERVICES (WST) stock?

WEST PHARMACEUTICAL SERVICES (WST) has a profitability rating of 7 / 10.


What is the financial health of WEST PHARMACEUTICAL SERVICES (WST) stock?

The financial health rating of WEST PHARMACEUTICAL SERVICES (WST) is 8 / 10.


What is the expected EPS growth for WEST PHARMACEUTICAL SERVICES (WST) stock?

The Earnings per Share (EPS) of WEST PHARMACEUTICAL SERVICES (WST) is expected to grow by 11.14% in the next year.